Skip to main content
. 2016 Feb 26;7(13):17047–17059. doi: 10.18632/oncotarget.7742

Figure 4. KU-0060648 inhibits PI3K-AKT-mTOR activation in HCC cells.

Figure 4

HepG2 A. Huh-7 B. and primary human HCC cells C. line-1) were treated with applied concentrations of KU-0060648 (“KU”) for indicated time, expressions of listed kinases and Tubulin were tested by Western blotting. Stable HepG2 cells expressing constitutively active AKT1 (CA-AKT1) or empty vector (“Ad-GFP”), were either left untreated (“Ctrl”), or treated with KU-0060648 (“KU”, 300 nM) for indicated time. Listed proteins were detected by Western blotting D. Cell proliferation E. and apoptosis F. were also tested. Expressions of listed kinases in HCC cells described in Figure 3 were tested G-J. Kinase phosphorylation (vs. total kinase) was quantified. Experiments in this figure were repeated three times, with similar results obtained. n=5 for each repeat (E and F). Bars stand for mean ± SD *p < 0.05.